The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Open accessAbstract
Mutations in the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) are a common feature of a major subset of primary human brain cancers. These mutations occur at a single amino acid residue of the IDH1 active site, resulting in loss of the enzyme's ability to catalyse conversion of isocitrate to alpha-ketoglutarate. However, only a single copy of the gene is mutated in tumours, raising the possibility that the mutations do not result in a simple loss of function. Here we show that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of alpha-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). Structural studies demonstrate that when arginine 132 is mutated to histidine, residues in the active site are shifted to produce structural changes consistent with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert alpha-ketoglutarate to 2HG. Excess accumulation of 2HG has been shown to lead to an elevated risk of malignant brain tumours in patients with inborn errors of 2HG metabolism. Similarly, in human malignant gliomas harbouring IDH1 mutations, we find markedly elevated levels of 2HG. These data demonstrate that the IDH1 mutations result in production of the onco-metabolite 2HG, and indicate that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [3]
In the citing paper
“Wild-type IDH1 and IDH2 catalyze the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (αKG) and CO2 (Figure 4a). Cancer associated mutations in IDH1 and IDH2 eliminate this function and confer a neomorphic activity to the enzyme, generating D-2-hydroxyglutarate (D-2HG) via the reduction of αKG (Figure 4b)(Dang et al., 2009; Ward et al., 2010).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Dang et al., 2009
In the citing paper
“cancer-associated IDH1 R132 mutants display a loss-of-function for the use of isocitrate as substrate, with a concomitant gain-of-function for the reduction of α-ketoglutarate to 2HG”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“There is a marked difference in the enzymatic rate of isocitrate-dependent NADPH production by the wild-type proteins and α-ketoglutarate-dependent NADPH consumption by both IDH1 and IDH2 mutants (Figure 2 and Dang et al., 2009).”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“2HG was found to be elevated in IDH1-mutated gliomas”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“The R132H IDH1 mutation observed in gliomas was found to display a gain of function for the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“In the case of IDH1 mutant proteins, it has been reported that a local supply of NADPH and α-ketoglutarate is required to drive 2HG production (Dang et al., 2009).”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Dang et al., 2009
In the citing paper
“Thus, various tumors, including glioma, secondary glioblastoma, and acute myeloid leukemia (AML), harboring heterozygous point mutations in the active sites of IDH1/2 show dramatic increases in the R-2-HG levels111,113–115.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [111]
In the citing paper
“Although additional studies are needed, ample experimental data support the recognition of R-2-HG, succinate, and fumarate as oncometabolites.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [111]
In the citing paper
“These results suggest that 2HG-and in particular the R-enantiomer produced by IDH1 mutants (Dang et al, 2009)-is probably an ineffective inhibitor of HIF Pro-hydroxylation, and predict that it would be relatively ineffective in inducing HIF1a.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“As production of 2HG by IDH mutations is stereospecific (Dang et al, 2009;Ward et al, 2010), the specificity of inhibition by the 2HG enantiomers is relevant to their potential as mediators of oncogenic pathways.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Dang et al, 2009
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Dang et al., 2009
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [121]
In the citing paper
“Oncogenic mutations in genes encoding IDH1/2 result in neomorphic enzyme activity that favors reduction of αKG to d-2-hydroxyglutarate (D-2HG) (167, 168).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [167]
In the citing paper
“This mutation alters the enzymatic ability of IDH1, allowing it to convert α-KG to 2-hydroxyglutarate (2-HG) rather than promote normal isocitrate–to–α-KG inter-conversion (78).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [78]
In the citing paper
“The weight of the evidence now suggests that regulation of HIF-1 stability through decreased PHD2 activity is not the primary effect of IDH mutations (Chowdhury et al., 2011; Dang et al., 2009; Jin et al., 2011; Mardis et al., 2009; Metellus et al., 2011; Williams et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“IDH1 mutations at R132 are not simply loss-of-function for isocitrate and α-ketoglutarate interconversion, but also acquire a novel reductive activity to convert α-ketoglutarate to 2-hydroxyglutarate (2HG)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“a rare metabolite found at only trace amounts in mammalian cells under normal conditions (Dang et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“R(-)-2HG (also known as D-2HG) is the exclusive 2HG stereoisomer produced by IDH1 and IDH2 mutants (Dang et al., 2009; Ward et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Dang et al., 2009
In the citing paper
“This suspicion was confirmed by metabolomics: tumor tissue and cell lines expressing mutant IDH1 or IDH2 produced large quantities of a metabolite, (D)-2-hydroxyglutarate (2-HG), that is vanishingly scarce when only the wild-type enzymes were expressed (Dang et al., 2009).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Dang et al., 2009
In the citing paper
“Surprisingly, even large accumulations of 2-HG do not cause wholesale perturbations of metabolite levels in IDH1-mutant tumors (Dang et al., 2009).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Dang et al., 2009
In the citing paper
“These findings therefore suggest that both suppression of RIP3-mediated necroptosis and MLK3-mediated apoptosis by D-2-HG may contribute to IDH-mutant carcinogenesis140,141.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
In the citing paper
“Finally, D-2HG also impairs necroptosis and the small GTPase Cdc42, leading to suppression of mixed lineage kinase 3 (MLK3)-mediated apoptosis140,141.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
In the citing paper
“D-2-HG has also been found to bind the DNA methyltransferase DNMT1, which subsequently represses receptor-interacting protein kinase 3 (RIP3).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
The CCP4 suite: programs for protein crystallography
Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,317
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,009
Mechanism and Function of Oxidative Reversal of DNA and RNA Methylation
Shen, L., Song, C., He, C., & Zhang, Y. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035513 · Cited by 369
Nutrient Sensing, Metabolism, and Cell Growth Control
Yuan, H.-X., Xiong, Y., & Guan, K. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.019 · Cited by 376
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcı́a-Prieto, C., Lu, W., Burger, J. A., Croce, C. M., Plunkett, W. K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2432 · Cited by 364
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation
Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., et al. (2017) · Nature · doi:10.1038/nature24294 · Cited by 354
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. T. (2016) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 348
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 359
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 363
Activity-based protein profiling for biochemical pathway discovery in cancer
Nomura, D. K., Dix, M. M., & Cravatt, B. F. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2901 · Cited by 347
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M. C., Zhu, L. D., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.28 · Cited by 349
Self-citationMetabolism of [U‐ 13 C]glucose in human brain tumors in vivo
Maher, E. A., Marin‐Valencia, I., Bachoo, R. M., Mashimo, T., Raisanen, J., Hatanpaa, K. J., Jindal, A., Jeffrey, F. M., Choi, C., Madden, C., et al. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2794 · Cited by 341
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 343
Araújo, W. L., Ishizaki, K., Nunes‐Nesi, A., Larson, T. R., Tohge, T., Krahnert, I., Witt, S., Obata, T., Schauer, N., Graham, I. A., et al. (2010) · The Plant Cell · doi:10.1105/tpc.110.075630 · Cited by 339
Barupal, D. K., & Fiehn, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-15231-w · Cited by 351
Mullen, A. R., Hu, Z., Shi, X., Jiang, L., Boroughs, L. K., Kovacs, Z., Boriack, R., Rakheja, D., Sullivan, L. B., Linehan, W. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.037 · Cited by 337
Metabolic Regulation of Histone Post-Translational Modifications
Fan, J., Krautkramer, K. A., Feldman, J. L., & Denu, J. M. (2015) · ACS Chemical Biology · doi:10.1021/cb500846u · Cited by 339
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
Peng, X., Chen, Z., Farshidfar, F., Xiaoyan, X., Lorenzi, P. L., Wang, Y., Cheng, F., Tan, L., Mojumdar, K., Du, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.077 · Cited by 338
Mullarky, E., Lucki, N. C., Beheshti Zavareh, R., Anglin, J. L., Gomes, A. P., Nicolay, B. N., Wong, J. C. Y., Christen, S., Takahashi, H., Singh, P. K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521548113 · Cited by 333
Self-citationBiological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 342
Chen, J., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 340
Stein, E. M., Dinardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R. H., Flinn, I. W., et al. (2018) · Blood · doi:10.1182/blood-2018-08-869008 · Cited by 330
Self-citationJankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C. J., O’Keefe, C. L., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311019 · Cited by 345
Qing, Y., Dong, L., Gao, L., Li, C., Li, Y., Han, L., Prince, E. A., Tan, B., Deng, X., Wetzel, C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.026 · Cited by 328
Metabolic signatures of cancer cells and stem cells
Intlekofer, A. M., & Finley, L. W. S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0032-0 · Cited by 322
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E. A., de la Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H. A., Jankú, F., Young, R. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03327 · Cited by 330
Self-citationDiagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Krämer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 334
The 2016 World Health Organization classification of tumours of the central nervous system
Villa, C., Miquel, C., Mosses, D., Bernier, M., & Stefano, A. L. D. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 322
Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0737-8 · Cited by 318
Self-citationTefferi, A., Lasho, T. L., Abdel-Wahab, O. I., Guglielmelli, P., Patel, J. L., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 327
Therapeutic targets in cancer cell metabolism and autophagy
Cheong, H., Lü, C., Lindsten, T., & Thompson, C. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2285 · Cited by 320
Self-citationLou, T., Sethuraman, D., Dospoy, P. D., Srivastva, P., Kim, H. S., Kim, J., Ma, X., Chen, P.-H., Huffman, K. E., Frink, R. E., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0287 · Cited by 330
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo
Venneti, S., Dunphy, M. P., Zhang, H., Pitter, K. L., Zanzonico, P., Campos, C., Carlin, S., Rocca, G. L., Lyashchenko, S. K., Plöessl, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1009 · Cited by 326
Self-citationKickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., von Deimling, A., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 318
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirović, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 332
The DNA methylation landscape in cancer
Skvortsova, K., Stirzaker, C., & Taberlay, P. C. (2019) · Essays in Biochemistry · doi:10.1042/ebc20190037 · Cited by 325
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Sulkowski, P. L., Oeck, S., Dow, J., Economos, N. G., Mirfakhraie, L., Liu, Y., Noronha, K. J., Bao, X., Li, J., Shuch, B. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2363-0 · Cited by 311
New aspects of the Warburg effect in cancer cell biology
Bensinger, S. J., & Christofk, H. R. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.02.003 · Cited by 322
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
Laukka, T., Mariani, C. J., Ihantola, T., Cao, J. Z., Hokkanen, J., Kaelin, W. G., Godley, L. A., & Koivunen, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.688762 · Cited by 307
Role of mitochondrial dysfunction in cancer progression
Hsu, C., Tseng, L., & Lee, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216641787 · Cited by 320
Mitochondrial function — gatekeeper of intestinal epithelial cell homeostasis
Rath, E., Moschetta, A., & Haller, D. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0021-x · Cited by 313
Dysregulated metabolism contributes to oncogenesis
Hirschey, M. D., DeBerardinis, R. J., Diehl, A. M., Drew, J. E., Frezza, C., Green, M. F., Jones, L. W., Ko, Y. H., Le, A., Lea, M. A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.10.002 · Cited by 316
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 309
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 309
Eight Kinetically Stable but Thermodynamically Activated Molecules that Power Cell Metabolism
Walsh, C. T., Tu, B. P., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00510 · Cited by 315
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
Mitochondrial DNA variation and cancer
Kopinski, P. K., Singh, L. N., Zhang, S., Lott, M. T., & Wallace, D. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00358-w · Cited by 301
Defining the Metabolome: Size, Flux, and Regulation
Zamboni, N., Saghatelian, A., & Patti, G. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.021 · Cited by 299
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296
Self-citationSasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
Self-citationMetabolic control of methylation and acetylation
Su, X., Wellen, K. E., & Rabinowitz, J. D. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.10.030 · Cited by 296
Self-citationTreatment of Relapsed Acute Myeloid Leukemia
Thol, F. R., & Ganser, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00765-5 · Cited by 295
The Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences
Cyr, A. R., & Domann, F. E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3492 · Cited by 301
Agnihotri, S., & Zadeh, G. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov125 · Cited by 302
Progress in understanding 2‐hydroxyglutaric acidurias
Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S., & Jakobs, C. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9462-5 · Cited by 292
Oncometabolite d -2HG alters T cell metabolism to impair CD8 + T cell function
Notarangelo, G., Spinelli, J. B., Perez, E. M., Baker, G. J., Kurmi, K., Elia, I., Stopka, S. A., Baquer, G., Lin, J., Golby, A. J., et al. (2022) · Science · doi:10.1126/science.abj5104 · Cited by 298
Fontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 303
Advances in mass spectrometry-based clinical biomarker discovery
Crutchfield, C. A., Thomas, S. N., Sokoll, L. J., & Chan, D. W. (2016) · Clinical Proteomics · doi:10.1186/s12014-015-9102-9 · Cited by 303
Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 295
TET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 297
Citrate – new functions for an old metabolite
Iacobazzi, V., & Infantino, V. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0271 · Cited by 295
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 295
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 292
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Intlekofer, A. M., Shih, A. H., Wang, B., Nazir, A., Rustenburg, A. S., Albanese, S. K., Patel, M., Famulare, C., Correa, F. M., Takemoto, N., et al. (2018) · Nature · doi:10.1038/s41586-018-0251-7 · Cited by 281
Self-citationBardella, C., El‐Bahrawy, M., Frizzell, N., Adam, J., Ternette, N., Hatipoglu, E., Howarth, K., O'Flaherty, L., Roberts, I., Turner, G., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2932 · Cited by 281
Mellinghoff, I. K., Peñas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Jankú, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0611 · Cited by 291
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer
Shim, E.-H., Livi, C. B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.-Y., Ghosh, A. P., Kirkman, R., Velu, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0696 · Cited by 280
Kung, H.-N., Marks, J. R., & Chi, J.-T. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002229 · Cited by 277
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K. S., Inagaki, A., Silber, J., Gorovets, D. J., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H. J., Chan, T. A.-T., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 283
Jia, D., Park, J. E., Jung, K., Levine, H., & Kaipparettu, B. A. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 283
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaïh, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 283
Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells
Saedeleer, C. J. D., Copetti, T., Porporato, P. E., Verrax, J., Féron, O., & Sonveaux, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046571 · Cited by 283
The functional roles of TCA cycle metabolites in cancer
Eniafe, J., & Jiang, S. (2021) · Oncogene · doi:10.1038/s41388-020-01639-8 · Cited by 289
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C. E., Rutka, J. T., & Zadeh, G. M. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 293
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
Jansen, M., Yip, S. S. F., & Louis, D. N. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70105-8 · Cited by 276
Revisiting the TCA cycle: signaling to tumor formation
Raimundo, N., Baysal, B. E., & Shadel, G. S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.001 · Cited by 281
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Green, C. L., Evans, C. M., Zhao, L., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2011) · Blood · doi:10.1182/blood-2010-12-322479 · Cited by 272
FTO controls reversible m6Am RNA methylation during snRNA biogenesis
Mauer, J., Sindelar, M., Despic, V., Guez, T., Hawley, B. R., Vasseur, J., Rentmeister, A., Gross, S. S., Pellizzoni, L., Debart, F., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0231-8 · Cited by 274
Self-citationSignaling in Control of Cell Growth and MetabolismPreprint
Ward, P. S., & Thompson, C. B. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006783 · Cited by 289
Self-citationMetabolite damage and its repair or pre-emption
Linster, C. L., SCHAFTINGEN, E. V., & Hanson, A. D. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1141 · Cited by 273
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & Martín, A. S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 276
L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH
Intlekofer, A. M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A. S., Salah, S., Gunner, M. R., Chodera, J. D., Cross, J. R., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2307 · Cited by 268
Self-citationMutant IDH1 and seizures in patients with glioma
Chen, H., Judkins, J., Thomas, C., Wu, M., Khoury, L., Benjamin, C., Pacione, D. R., Golfinos, J. G., Kumthekar, P., Ghamsari, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003911 · Cited by 270
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 281
Im, A., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M. M. (2014) · Leukemia · doi:10.1038/leu.2014.124 · Cited by 278
Functions of the sirtuin deacylase SIRT5 in normal physiology and pathobiology
Kumar, S., & Lombard, D. B. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1458071 · Cited by 273
Horak, P., Griffith, M., Danos, A. M., Pitel, B. A., Madhavan, S., Liu, X., Chow, C., Williams, H. E., Carmody, L., Barrow-Laing, L., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.01.001 · Cited by 268
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Sutendra, G., & Michelakis, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00038 · Cited by 275
Johnson, K. C., Anderson, K. J., Courtois, E. T., Gujar, A. D., Barthel, F. P., Varn, F. S., Luo, D., Seignon, M., Yi, E. S., Kim, H., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00926-8 · Cited by 277
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. Q. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 266
An Overview: The Diversified Role of Mitochondria in Cancer Metabolism
Liu, Y., Sun, Y., Guo, Y., Shi, X., Chen, X., Feng, W., Wu, L., Zhang, J., Yu, S., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81609 · Cited by 275
Landscape of TET2 mutations in acute myeloid leukemia
Weißmann, S., Alpermann, T., Grossmann, V., Kowarsch, A., Nadarajah, N., Eder, C., Dicker, F., Fasan, A., Haferlach, C., Haferlach, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.326 · Cited by 272
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I. H., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 264
Metabolite discovery through global annotation of untargeted metabolomics data
Chen, L., Lu, W., Wang, L., Xing, X., Chen, Z., Teng, X., Zeng, X., Muscarella, A. D., Shen, Y., Cowan, A. J., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01303-3 · Cited by 266
Self-citationCorrelation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöehrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 265
Núñez, F. J., Mendez, F., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C. J., Calinescu, A., Kamran, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1427 · Cited by 264
Detection and analysis of chiral molecules as disease biomarkers
Liu, Y., Wu, Z., Armstrong, D. W., Wolosker, H., & Zheng, Y. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00476-z · Cited by 261
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq497 · Cited by 261
Li, L., & Li, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.004 · Cited by 257
Metadata
- Authors
- Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., Prins, R. M., Ward, P. S., Yen, K. E., Liau, L. M., Rabinowitz, J. D., Cantley, L. C., Thompson, C. B., Vander Heiden, M. G., & Su, S. M.
- Affiliations
- Agios Pharmaceuticals (United States) (US)
- Princeton University (US)
- University of California, Los Angeles (US)
- Abramson Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- ORCID
- Venue
- Nature
- Published
- 2009-11-22
- Volume
- 462
- Issue
- 7274
- Pages
- 739-744
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2818760
- OpenAlex
- W2080452140
- Cited by
- 4,154
- References
- 26
- Citations by year
- 2026: 184 · 2025: 230 · 2024: 250 · 2023: 257 · 2022: 285 · 2021: 315 · 2020: 297 · 2019: 267 · 2018: 280 · 2017: 270 · 2016: 273 · 2015: 245 · 2014: 218 · 2013: 225 · 2012: 218
- FWCI
- 88.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-06-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P01CA104838, R21CA128620, R01CA105463)
- National Institute of Biomedical Imaging and Bioengineering (P30EB009998)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Keywords
- IDH1 mutation, 2-hydroxyglutarate, gain-of-function mutations, isocitrate dehydrogenase, high-grade glioma, glioblastoma, oncometabolites, carcinogenesis, brain cancer, enzyme structure, tumor progression
- MeSH terms
- Arginine, Brain Neoplasms, Cell Line, Glioma, Glutarates, Histidine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Mutation, Protein Conformation, Crystallography, X-Ray, Disease Progression, Catalytic Domain, Mutant Proteins, Enzyme Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
